CD274 and neoplasm: For example, pembrolizumab, a PD-L1 antagonistic monoclonal antibody, as a first-line therapy for patients with PD-L1-positive mTNBC, exerts robust anti-tumor activity3; in addition, the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib, may be effective against BRCA mutated-mTNBC4, and the combination of olaparib and chemotherapy appears to be a promising approach for increasing treatment efficacy in BRCA mutated-TNBC5–7.